Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens

Antibody signatures may become sophisticated screening tools for early diagnosis and the development of personalized anticancer treatments. We used biopanning to enrich the immune response of head and neck squamous cell carcinoma (HNSCC) patients. This method revealed a HNSCC-specific antibody signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Scanlon, Christina Springstead, D’Silva, Nisha J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654574/
https://www.ncbi.nlm.nih.gov/pubmed/23734304
http://dx.doi.org/10.4161/onci.23433
_version_ 1782269582762835968
author Scanlon, Christina Springstead
D’Silva, Nisha J.
author_facet Scanlon, Christina Springstead
D’Silva, Nisha J.
author_sort Scanlon, Christina Springstead
collection PubMed
description Antibody signatures may become sophisticated screening tools for early diagnosis and the development of personalized anticancer treatments. We used biopanning to enrich the immune response of head and neck squamous cell carcinoma (HNSCC) patients. This method revealed a HNSCC-specific antibody signature and allowed for the discovery of a novel oncogene, L23.
format Online
Article
Text
id pubmed-3654574
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545742013-06-03 Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens Scanlon, Christina Springstead D’Silva, Nisha J. Oncoimmunology Author's View Antibody signatures may become sophisticated screening tools for early diagnosis and the development of personalized anticancer treatments. We used biopanning to enrich the immune response of head and neck squamous cell carcinoma (HNSCC) patients. This method revealed a HNSCC-specific antibody signature and allowed for the discovery of a novel oncogene, L23. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654574/ /pubmed/23734304 http://dx.doi.org/10.4161/onci.23433 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Scanlon, Christina Springstead
D’Silva, Nisha J.
Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
title Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
title_full Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
title_fullStr Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
title_full_unstemmed Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
title_short Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
title_sort personalized medicine for cancer therapy: lessons learned from tumor-associated antigens
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654574/
https://www.ncbi.nlm.nih.gov/pubmed/23734304
http://dx.doi.org/10.4161/onci.23433
work_keys_str_mv AT scanlonchristinaspringstead personalizedmedicineforcancertherapylessonslearnedfromtumorassociatedantigens
AT dsilvanishaj personalizedmedicineforcancertherapylessonslearnedfromtumorassociatedantigens

Ejemplares similares